Midyear report 2022
High-precision delivery
medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. On September 30, 2021, medmix spun off from Sulzer. Its shares are since listed and traded on the SIX Swiss Exchange in Zurich (Securities No. 112.967.710/ISIN CH1129677105). This is the first midyear report of medmix as an independent group of companies.
Read more about medmix here
Letter to the shareholders
Our KEY Figures
250.6 m CHF
revenue in H1 2022
24.0 %
adjusted EBITDA margin
14.3 m CHF
free cash flow generated in H1 2022
Financial and business review
Financial reporting
